Harvard Pilgrim Health Care Home
  HPHConnect
 
  Learn more.
  Sign up for HPHConnect.
Medical Management
E-Transactions
HPHConnect
Pharmacy
For Your Patient
News Center
Network Matters
Newsletter Archives
Newsletter Registration
Newsroom
Office Support
Products
Provider Manual
Medicare Advantage
Research & Teaching
Resources & Links
 
Print    Text Size

Network Matters
News and Information for the
Harvard Pilgrim Health Care Network

May 2020

Updates to Cardiovascular Disease Risk Tests Medical Policy


Effective for dates of service beginning July 1, 2020 for our commercial members, Harvard Pilgrim is updating our Cardiovascular Disease Risk Tests Medical Policy and will no longer cover the following CPT codes when reported with certain diagnoses:

  • 83880 – Natriuretic peptide
  • 85384 – Fibrogen, activity
  • 0052U – Lipoprotein, blood, high resolution fractionation and quantitation of lipoproteins, including all five major lipoprotein classes and subclasses of HDL, LDL and VLDL by vertical auto profile ultracentrifugation

In addition, the following tests are being added to the updated policy’s list of coverage exclusions:

  • B-type natriuretic peptide
  • Glycosylated acute phase proteins (GlycA)
  • Interleukin 6, 17, 18
  • Mid-regional pro-atrial natriuretic peptide
  • Molecular lipid/metabolic profiling (e.g., lipidomic, metabolomics)
  • Pregnancy-associated plasma protein-A (PAPP-A)
  • Protein C
  • Prothrombotic factors (antithrombin III, PAI-1, tPA, Factor V Leiden)
  • Soluble cell adhesion molecules (e.g. VCAM-1, ICAM-1)
  • Transforming growth factor beta
  • Troponin

For complete information, please refer to Harvard Pilgrim’s updated Cardiovascular Disease Risk Tests Medical Policy.

Email this article to a colleague   


Network Matters Archives

Download printer-friendly version

HPHCURRENT EVENTS

Latest Information for Providers: COVID-19 Resources Updated

Drive-Through Testing Site for COVID-19

CLINICIAN CORNER

Home Infusions for Eligible Patients to Promote Social Distancing

Updates to Cardiovascular Disease Risk Tests Medical Policy

InterQual Criteria for Oral Devices for Obstructive Sleep Apnea

Khapzory Prior Authorization: Coding Update

PUBLICATION INFORMATION

Robert Farias,
Senior Vice President, Corporate Network Strategy

Helen Connaughton,
Director, Network Operations

Annmarie Dadoly,
Editor

Joseph O'Riordan,
Writer

Kristin Edmonston,
Production Coordinator